Lendormin D® Tablet (Drug Use Result Survey)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02224014

Enrollment

485

Registered

2014-08-22

Start date

2005-06-30

Completion date

Unknown

Last updated

2014-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Initiation and Maintenance Disorders

Brief summary

Study to investigate the safety and the efficacy in patients with insomnia, receiving Lendormin D tablet under condition of normal clinical practice.

Interventions

DRUGLendormin D tablets

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with insomnia

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
Number of patients with serious adverse events	up to 2 months
Number of patients with adverse events	up to 2 months
Number of patients with adverse drug reactions	up to 2 months

Secondary

Measure	Time frame
Physician's overall efficacy assessment on a 3-point scale	up to 2 months
Patient's impression questionnaire	up to 2 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026